BioXcel Therapeutics, Inc. (BTAI) Cash Flow Statement
Where BTAI’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$57.6M
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$57.6M −8,974.3% margin
- Returned to shareholders
- —
- Change in cash
- −$1.1M cash at year-end $28.8M
Cash from operations
−$57.6M
Shares issued
+$58.1M
Other financing
−$1.6M
Change in cash
−$1.1M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BTAI operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
BTAI cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.3M2016 | −$57.6M2025 | — | |
| Capital expenditures | $4,0002016 | $02025 | −100.0% | |
| Free cash flow | −$1.3M2016 | −$57.6M2025 | — | |
| Free cash flow margin | −274,345,679.0%2020 | −8,974.3%2025 | +274,336,704.7 pts | |
| Stock-based compensation | $671,0002016 | $2.8M2025 | +17.0%/yr | |
| Share buybacks (net) | $02016 | $27,0002023 | — | |
| Capex / revenue | 1,300,411.5%2020 | 0.0%2025 | −1,300,411.5 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BTAI cash flow by activity
OperatingInvestingFinancingChange in cash
BTAI net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BTAI cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$69.9M | −$59.6M | −$179.1M | −$165.8M | −$106.9M | −$82.2M | −$33.0M | −$19.3M | −$4.5M | −$2.1M |
| Depreciation & amortization | $300,000 | $309,000 | $318,000 | $327,000 | $297,000 | $188,000 | $156,000 | $17,000 | $1,000 | $2.1M |
| Stock-based compensation | $2.8M | $6.2M | $18.6M | $17.3M | $19.5M | $14.6M | $3.1M | $3.1M | $1.6M | $671,000 |
| Change in working capital | −$1.7M | −$6.0M | $2.0M | $10.4M | $5.0M | $1.0M | $2.4M | $2.7M | $736,000 | $155,000 |
| Other non-cash items | $10.9M | −$12.9M | $3.1M | $2.3M | $46,000 | $0 | $0 | $0 | $0 | −$2.1M |
| Cash from operating activities | −$57.6M | −$72.0M | −$155.0M | −$135.3M | −$82.2M | −$66.3M | −$27.3M | −$13.5M | −$2.2M | −$1.3M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | −$20,000 | −$139,000 | −$445,000 | −$316,000 | −$870,000 | −$340,000 | −$340,000 | −$4,000 |
| Investments (net) | — | $0 | −$20,000 | −$139,000 | −$445,000 | −$316,000 | −$870,000 | −$340,000 | $0 | −$4,000 |
| Acquisitions & other investing | — | — | $20,000 | $139,000 | $445,000 | $316,000 | $870,000 | $340,000 | $0 | $4,000 |
| Cash from investing activities | — | — | −$20,000 | −$139,000 | −$445,000 | −$316,000 | −$870,000 | −$340,000 | −$340,000 | −$4,000 |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | −$27,000 | $283,000 | $102.4M | −$9.0M | $17.8M | $56.5M | $2.1M | $1.3M |
| Net borrowing (repayment) | $0 | −$2.5M | $0 | $96.0M | $98.6M | $98.6M | $179,000 | −$371,000 | $811,000 | $811,000 |
| Shares issued | $58.1M | $39.7M | $24.7M | $24.7M | $101.0M | $255.8M | $17.8M | $56.5M | $0 | $0 |
| Other financing | −$1.6M | −$528,000 | $1.9M | −$24.7M | −$199.6M | −$98.0M | −$17.8M | −$57.1M | $211,000 | −$811,000 |
| Cash from financing activities | $56.5M | $36.7M | $26.5M | $96.2M | $102.4M | $247.4M | $18.0M | $55.5M | $3.1M | $1.3M |
| Summary | ||||||||||
| Net change in cash | −$1.1M | −$35.4M | −$128.5M | −$39.2M | $19.8M | $180.7M | −$10.1M | $41.7M | $887,000 | $1.3M |
| Cash at end of period | $28.8M | $29.9M | $65.2M | $193.7M | $233.0M | $213.1M | $32.4M | $42.6M | $887,000 | — |
| Free cash flow | −$57.6M | −$72.0M | −$155.0M | −$135.5M | −$82.6M | −$66.7M | −$28.1M | −$13.8M | −$2.2M | −$1.3M |
| Free cash flow margin | −8,974.3% | −3,178.6% | −11,233.8% | −36,128.0% | — | −274,345,679.0% | — | — | — | — |
| Capex / revenue | 0.0% | 0.0% | 1.4% | 37.1% | — | 1,300,411.5% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$14.7M | −$12.7M | −$12.5M | −$30.9M | −$19.2M | −$7.3M | −$10.9M | −$13.7M | −$8.3M | −$26.8M | −$22.3M | −$50.5M |
| Depreciation & amortization | $18,000 | $58,000 | $74,000 | $75,000 | $75,000 | $76,000 | $77,000 | $77,000 | $77,000 | $78,000 | $78,000 | $79,000 |
| Stock-based compensation | $358,000 | $435,000 | $450,000 | $581,000 | $1.6M | $180,000 | −$199,000 | $1.9M | $1.1M | $3.4M | $3.6M | $4.0M |
| Change in working capital | $3.7M | $1.4M | −$928,000 | −$1.6M | $2.4M | −$1.6M | −$3.6M | −$1.3M | −$5.4M | $4.3M | −$9.4M | $7.9M |
| Other non-cash items | $4.6M | −$961,000 | −$1.3M | $13.1M | $2.6M | −$3.5M | −$273,000 | −$3.3M | −$10.6M | $1.3M | $1.1M | $862,000 |
| Cash from operating activities | −$6.1M | −$11.8M | −$14.2M | −$18.8M | −$12.6M | −$12.0M | −$14.8M | −$16.3M | −$23.2M | −$17.7M | −$26.9M | −$37.6M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | — | −$8,000 | — | $27,000 | — |
| Net borrowing (repayment) | −$304,000 | −$8.1M | — | — | $0 | $0 | — | — | — | — | — | — |
| Shares issued | $3.1M | $8.5M | $5.8M | $38.2M | $140,000 | $14.0M | $7.0M | $468,000 | $5.5M | $26.7M | $2.4M | $0 |
| Other financing | −$86,000 | −$158,000 | −$115,000 | −$702,000 | −$3,000 | −$804,000 | −$2.7M | −$14,000 | −$164,000 | −$117,000 | −$279,000 | −$237,000 |
| Cash from financing activities | $2.7M | $232,000 | $5.6M | $37.5M | $137,000 | $13.2M | $4.3M | $454,000 | $5.3M | $26.6M | $2.1M | −$237,000 |
| Summary | ||||||||||||
| Net change in cash | −$3.4M | −$11.6M | −$8.6M | $18.7M | −$12.4M | $1.2M | −$10.5M | −$15.9M | −$17.9M | $8.9M | −$24.7M | −$37.6M |
| Cash at end of period | $13.8M | $17.2M | $28.8M | $37.3M | $18.6M | $31.0M | $29.9M | $40.4M | $56.3M | $74.1M | $65.2M | $90.0M |
| Free cash flow | −$6.1M | −$11.8M | −$14.2M | −$18.8M | −$12.6M | −$12.0M | −$14.8M | −$16.3M | −$23.2M | −$17.7M | −$26.9M | −$37.6M |
| Free cash flow margin | −3,350.5% | −5,732.5% | −5,550.8% | −19,170.4% | −10,479.2% | −7,168.5% | −4,046.2% | −7,634.6% | −2,099.1% | −3,042.3% | −7,144.4% | −11,021.7% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BTAI cash generation
In fiscal 2025 (ended December 31, 2025), BioXcel Therapeutics generated -$57.6 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$57.6 million, −8,974.3% of revenue. Cash and equivalents fell by $1.1 million over the year.
Related: BTAI income statement, BTAI balance sheet. See the BTAI stock overview for the latest quote and news.
BTAI cash flow FAQ
What is BioXcel Therapeutics's free cash flow?
BioXcel Therapeutics's free cash flow was -$57.6 million in fiscal 2025: -$57.6 million of operating cash flow minus $0 of capital expenditures It was -$72.0 million a year earlier..
How much cash does BioXcel Therapeutics generate from operations?
BioXcel Therapeutics generated -$57.6 million of cash from operating activities in fiscal 2025.